Evaluating ICP-192 for patients with advanced intrahepatic cholangiocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a single-arm, open-label, multi-center phase 2 evaluation of ICP-192, aimed at assessing its efficacy and safety in patients with FGFR2-rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who have not responded to prior therapies. Participants must have a confirmed diagnosis of intrahepatic cholangiocarcinoma and meet specific eligibility criteria, including having measurable lesions and adequate organ function. The study will monitor the treatment's impact on tumor progression and overall patient health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed the ICF and Age ≥ 18 years old, either sex.
2. ECOG score of 0-1.
3. Life expectancy \> 3 months.
4. Histopathologically or cytopathologically confirmed intrahepatic cholangiocarcinoma with unresectable, recurrent or metastatic (AJCC 2017, 8th edition, TNM stage IV) tumor that has progressed following at least one line of chemotherapy and progression/recurrence within 6 months after neoadjuvant/adjuvant chemotherapy may be included.
5. FGFR2 fusion /rearrangement as confirmed by the central laboratory.
6. At least one measurable lesion at screening as target lesion per RECIST 1.1.
7. Organ functions meeting the protocol requirements.
8. Contraception according to the protocol requirements.

Exclusion Criteria:

1. Presence of other malignancies requiring medical intervention.
2. Prior treatment with selective FGFR inhibitors or FGFR antibodies.
3. Treatment with biological products, radical radiotherapy, and other investigational drugs within 4 weeks prior to the first dose of study drug. Chemotherapy within 3 weeks prior to the first dose of study drug.
4. Known symptomatic central nervous system (CNS) metastases.
5. Patients who have not recovered from the toxicity caused by previous anti-tumor treatment and have ≥ Grade 2 adverse events (judged per CTCAE V5.0 evaluation criterion) at the first dose of study drug.
6. Currently uncontrolled cardiovascular and cerebrovascular diseases, or a past medical history.
7. Any unstable or uncontrolled systemic disease as judged by the investigator, such as: active infection requiring intravenous therapy, uncontrolled hypertension (After treatment systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 90 mmHg), and diabetes mellitus (HbA1c \> 8%).
8. Current active bleeding, such as deep venous thrombosis, portal hypertension signs leading to gastroesophageal venous bleeding.
9. Wound with active infection.
10. Major surgical procedures within 4 weeks prior to the first dose of the study drug or minor surgical procedures within 2 weeks prior to the first dose of the study drug.
11. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity
12. History and/or current evidence of extensive tissue calcification, including but not limited to calcification in soft tissues, kidney, intestine, myocardium, vasculature and/or the lungs, with the exception of lymph node calcification, mild pulmonary parenchymal calcification, and asymptomatic coronary artery calcification.
13. Clinically serious gastrointestinal dysfunction that may affect the intake, transport or absorption of the study drug (such as poorly controlled nausea, vomiting, diarrhea; malabsorption syndrome; intestinal obstruction and small bowel resection, etc.), or the patient was unable to swallow the drug orally.
14. Active HBV infection, Active HCV infection, HIV infection.
15. Female subjects who are pregnant or breastfeeding, or plan to have a pregnancy within 6 months after the last dose of the study drug; or male subjects who plan to father a child during the study or within 6 months after the last dose of the study drug.
16. The last dose of strong CYP3A inhibitor or CYP3A inducer (including food, western medicine, traditional Chinese medicine) is less than 5 half-lives before the first dose of study drug, or plans to take concomitant drugs or foods with strong CYP3A inhibition or induction during the study.
17. Known allergy to any excipients of the study drug.
18. Subjects with conditions that in the investigator's opinion are not suitable for participating in this trial.

Where it's running

• Beijing Hospital
  Beijing, Beijing Municipality, China Recruiting
• ZhuJiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting
• Hunan Cancer Hospital
  Changsha, Hunan, China Recruiting
• Qilu Hospital
  Jinan, Shandong, China Recruiting
• Jinan Central Hospital
  Jinan, Shandong, China Recruiting
• Anhui Provincial Hospital
  Hefei, Anhui, China Not yet recruiting

Study contacts

• Principal investigator: Jin Li — Shanghai East Hospital
• Study coordinator: Jin Li
• Email: lijin@csco.org.cn
• Phone: 021-38804518

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma

  This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07847710

• Protective effect of phycocyanin on liver injury after partial hepatectomy

  This study tests whether taking phycocyanin around liver surgery can reduce liver injury and help the liver recover in adults with intrahepatic cholangiocarcinoma.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07760038

• Adjuvant therapy after liver surgery for high-risk intrahepatic cholangiocarcinoma

  This real-world study tests three adjuvant treatment approaches after curative liver surgery in people with high-risk intrahepatic cholangiocarcinoma to see which option performs best.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07640048

• Scout-dose check using resin microspheres before yttrium-90 treatment for liver tumors

  This test tries a small 'scout' dose of the same resin microspheres used in yttrium-90 treatment to better measure lung shunt in adults with liver cancer or liver metastases.

  Recruiting Seoul National University Hospital · Seoul · NCT07476651

• 68Ga‑FAPI PET/CT imaging for biliary tract cancers

  We will test whether 68Ga‑FAPI PET/CT scans can find and stage gallbladder cancer and intrahepatic cholangiocarcinoma more accurately than standard FDG PET/CT in adults with suspected or known disease.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT07337850

• Blood test using cfDNA methylation to screen for biliary tract cancers

  This study tests whether a blood test that reads cfDNA methylation can detect biliary tract cancers early in adults with or suspected of having these cancers.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07176962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.